[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:clear-cell-sarcoma-of-soft-tissue":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"Clear Cell Sarcoma of Soft Tissue",4,[7,15,21,27],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06942442","A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma",[11],"Phase 2","RECRUITING","2026-08-26T02:18:06.247899Z","2026-04-29T02:57:57.069911Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":13,"content_modified":20},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[19],"Phase 1\u002FPhase 2","2026-07-19T19:36:05.068230Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[19],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[31],"Phase 1","2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",[],[]]